The use of SGLT2 inhibitors in patients with recent AHF events proved to be effective in improving outcomes and enhancing clinical benefits.22–24 While the PIONEER-HF and PARAGLIDE-HF trials included relatively few patients undergoing SGLT2 inhibitor treatment,8 in the PREMIER study, ∼60% of patients were on SGLT2 inhibitor therapy at randomization; Sac/Val therapy reduced NT-proBNP levels irrespective of SGLT2 inhibitor use. Here, SLC5A2 is linked to hydrops fetalis.